The specific non-peptide B2R antagonist LF 16-0687 (Anatibant) can also effectively reduce the inflammatory response, BBB disruption, and infarct growth, and had a neuroprotective effect after stroke (Zausinger et al., 2002). The gene discussed is BDKRB2; the disease is stroke disorder.